Genetic Epidemiology and Genomics Laboratory, Division of Epidemiology, School of Public Health, University of California, Berkeley, CA 94720-7356, USA.
Hum Mol Genet. 2010 Jun 1;19(11):2331-40. doi: 10.1093/hmg/ddq101. Epub 2010 Mar 8.
The MHC class II transactivator gene (CIITA) is an important transcription factor regulating gene required for HLA class II MHC-restricted antigen presentation. Association with HLA class II variation, particularly HLA-DRB11501, has been well-established for multiple sclerosis (MS). In addition, the -168A/G CIITA promoter variant (rs3087456) has been reported to be associated with MS. Thus, a multi-stage investigation of variation within CIITA, DRB11501 and MS was undertaken in 6108 individuals. In stage 1, 24 SNPs within CIITA were genotyped in 1320 cases and 1363 controls (n = 2683). Rs4774 (missense +1614G/C; G500A) was associated with MS (P = 4.9 x 10(-3)), particularly in DRB11501 +individuals (P = 1 x 10(-4)). No association was observed for the -168A/G promoter variant. In stage 2, rs4774 was genotyped in 973 extended families; rs4774C was also associated with increased risk for MS in DRB11501+ families (P = 2.3 x 10(-2)). In a third analysis, rs4774 was tested in cases and controls (stage 1) combined with one case per family (stage 2) for increased power. Rs4774C was associated with MS (P = 1 x 10(-3)), particularly in DRB11501+ cases and controls (P = 1 x 10(-4)). Results obtained from logistic regression analysis showed evidence for interaction between rs4774C and DRB11501 associated with risk for MS (ratio of ORs = 1.72, 95% CI 1.28-2.32, P = 3 x 10(-4)). Furthermore, rs4774C was associated with DRB11501+ MS when conditioned on the presence (OR = 1.67, 95% CI = 1.19-2.37, P = 1.9 x 10(-3)) and absence (OR = 1.49, 95% CI = 1.15-1.95, P = 2.3 x 10(-3)) of CLEC16A rs6498169G, a putative MS risk allele adjacent to CIITA. Our results provide strong evidence supporting a role for CIITA variation in MS risk, which appears to depend on the presence of DRB1*1501.
MHC 类 II 转录激活因子基因(CIITA)是调节 HLA 类 II MHC 限制性抗原呈递所需的重要转录因子。与 HLA 类 II 变异,特别是 HLA-DRB11501 的关联,已在多发性硬化症(MS)中得到充分证实。此外,-168A/G CIITA 启动子变异(rs3087456)已被报道与 MS 相关。因此,在 6108 个人中进行了 CIITA、DRB11501 和 MS 内变异的多阶段研究。在第 1 阶段,在 1320 例病例和 1363 例对照(n=2683)中对 CIITA 内的 24 个 SNP 进行了基因分型。rs4774(错义+1614G/C;G500A)与 MS 相关(P=4.9×10(-3)),尤其是在 DRB11501+个体中(P=1×10(-4))。-168A/G 启动子变异没有观察到关联。在第 2 阶段,在 973 个扩展家族中对 rs4774 进行了基因分型;rs4774C 也与 DRB11501+家族中 MS 的风险增加相关(P=2.3×10(-2))。在第三次分析中,在病例和对照(第 1 阶段)中测试了 rs4774,并结合每个家庭中的一个病例(第 2 阶段)以增加效力。rs4774C 与 MS 相关(P=1×10(-3)),尤其是在 DRB11501+病例和对照中(P=1×10(-4))。逻辑回归分析结果表明,rs4774C 与 DRB11501 之间存在与 MS 风险相关的相互作用的证据(OR 比值=1.72,95%CI 1.28-2.32,P=3×10(-4))。此外,当条件为存在(OR=1.67,95%CI=1.19-2.37,P=1.9×10(-3))和不存在(OR=1.49,95%CI=1.15-1.95,P=2.3×10(-3))CLEC16A rs6498169G 时,rs4774C 与 DRB11501+MS 相关,CLEC16A rs6498169G 是紧邻 CIITA 的假定 MS 风险等位基因。我们的结果提供了强有力的证据,支持 CIITA 变异在 MS 风险中的作用,这似乎取决于 DRB11501 的存在。